Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes

被引：11

作者：

Tamburini, J. ^{[1
]}

Elie, C. ^{[2
]}

Park, S. ^{[1
]}

Beyne-Rauzy, O. ^{[3
]}

Gardembas, M. ^{[4
]}

Berthou, C. ^{[5
]}

Mahe, B. ^{[6
]}

Sanhes, L. ^{[7
]}

Stamatoullas, A. ^{[8
]}

Vey, N. ^{[9
]}

Aouba, A.

Slama, B. ^{[10
]}

Quesnel, B. ^{[11
]}

Vekhoff, A. ^{[13
]}

Sotto, J. J. ^{[12
]}

Vassilief, D. ^{[1
]}

Al-Nawakil, C. ^{[1
]}

Fenaux, P. ^{[14
]}

Dreyfus, F. ^{[1
]}

Bouscary, D. ^{[1
]}

机构：

[1] Hop Cochin, Dept Haematol, Paris, France

[2] Univ Paris 05, Dept Biostat, F-75270 Paris 06, France

[3] Hop Purpan, Dept Hematol Odile, Toulouse, France

[4] Ctr Hosp Angers, Dept Hematol Martine, Angers, France

[5] Hop Brest, Dept Hematol Christian, Brest, France

[6] Ctr Hosp Nantes, Dept Hematol, Nantes, France

[7] Ctr Hosp Perpignan, Dept Hematol, Perpignan, France

[8] Ctr Hosp Rouen, Dept Hematol Aspasia, Rouen, France

[9] Inst J Paoli I Calmettes, Dept Hematol, F-13009 Marseille, France

[10] Ctr Hosp Avignon, Dept Hematol, Avignon, France

[11] Ctr Hosp Lille, Dept Hematol, Lille, France

[12] Ctr Hosp Grenoble, Dept Hematol, Grenoble, France

[13] Hop Hotel Dieu, Dept Hematol, F-75181 Paris, France

[14] Hop Avicenne, Dept Hematol, Bobigny, France

来源：

LEUKEMIA RESEARCH | 2009年 / 33卷 / 04期

关键词：

INTERNATIONAL WORKING GROUP; RESPONSE CRITERIA; ANEMIA; PROPOSAL;

D O I：

10.1016/j.leukres.2008.06.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：547 / 550

页数：4

共 50 条

[21] MECHANISTIC HIGHLIGHTS OF IMPROVED ERYTHROPOIESIS WITH A LOW DOSE OF DEFERASIROX IN LOW RISK MYELODYSPLASTIC SYNDROMES
Mathieu, M.
Ancelet, S.
Lefebvre, C.
Arnaud, J.
Garrel, C.
Pezet, M.
Wang, Y.
Faure, P.
Szymanski, G.
Polack, B.
Cahn, J. Y.
Moulis, J. M.
Park, S.
HAEMATOLOGICA, 2017, 102 : 483 - 483
[22] Mannuronic Acid in Low-Risk and Intermediate-1-Risk Myelodysplastic Syndromes
Ghaderi, Afshin
Nodehi, Sayyed Reza Safaee
Bakhtiari, Tahereh
Aslani, Mona
Aghazadeh, Zahra
Matsuo, Hidenori
Rehm, Bernd H. A.
Cuzzocrea, Salvatore
Mirshafiey, Abbas
JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (07): : 879 - 888
[23] Response assessments in low-risk and high-risk myelodysplastic syndromes (MDS)
Fenaux, P
SEMINARS IN ONCOLOGY, 2005, 32 (04) : S11 - S15
[24] Cigarette smoking shortens the survival of patients with low-risk myelodysplastic syndromes
Ma, Xiaomei
Wang, Rong
Galili, Naomi
Mayne, Susan T.
Wang, Sa A.
Yu, Herbert
Raza, Azra
CANCER CAUSES & CONTROL, 2011, 22 (04) : 623 - 629
[25] A decision analysis to determine the appropriate treatment for low-risk myelodysplastic syndromes
Sekeres, Mikkael A.
Fu, Alex Z.
Maciejewski, Jaroslaw R.
Golshayan, Ali-Reza
Kalaycio, Matt E.
Kaftan, Michael W.
CANCER, 2007, 109 (06) : 1125 - 1132
[26] Use of steroids in the management of low-risk myelodysplastic syndromes with autoimmune features
Fattizzo, Bruno
Serpenti, Fabio
Versino, Francesco
Cassanello, Giulio
Cro, Lilla M.
Barbieri, Marzia
Croci, Giorgio A.
Revelli, Nicoletta
Porta, Matteo G. Della
Barcellini, Wilma
BLOOD TRANSFUSION, 2023, 21 (05) : 452 - 460
[27] Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes
R. Tehranchi
Medical Oncology, 2006, 23 (1) : 37 - 49
[28] Impact of growth factors in the regulation of apoptosis in low-risk myelodysplastic syndromes
Tehranchi, R
MEDICAL ONCOLOGY, 2006, 23 (01) : 37 - 49
[29] Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies
Molica, Matteo
Rossi, Marco
EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (04) : 233 - 241
[30] Cigarette smoking shortens the survival of patients with low-risk myelodysplastic syndromes
Xiaomei Ma
Rong Wang
Naomi Galili
Susan T. Mayne
Sa A. Wang
Herbert Yu
Azra Raza
Cancer Causes & Control, 2011, 22 : 623 - 629

← 1 2 3 4 5 →